Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival

European Journal of Haematology

Volumn 84, Issue 2, 2010, Pages 105-108

  Patnaik, Mrinal M ^a   Caramazza, Domenica ^b   Gangat, Naseema ^a   Hanson, Curtis A ^c   Pardanani, Animesh ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF PALERMO   (Italy)

^c Division of Hematopathology   (United States)

Author keywords

Myelofibrosis; Prognosis; Survival; Young

Indexed keywords

ADULT; AGE; AGE DISTRIBUTION; ARTICLE; DATA BASE; DEATH; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; MYELOID METAPLASIA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SURVIVAL; SURVIVAL TIME; THROMBOCYTE COUNT;

ADOLESCENT; ADULT; AGE FACTORS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PLATELET COUNT; PRIMARY MYELOFIBROSIS; RISK FACTORS; SURVIVAL RATE;

EID: 74049116496     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2009.01373.x     Document Type: Article

References (17)

1. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000 342 : 1255 1265.
2. Tefferi A, Skoda R, Vardiman JW. Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. Nat Rev Clin Oncol 2009 6 : 627 637.
3. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009 113 : 2895 2901.
4. Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 2005 105 : 973 977.
5. Tefferi A. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. Am J Hematol 2008 83 : 491 497.
6. Kroger N, Badbaran A, Holler E, Hahn J, Kobbe G, Bornhauser M, Reiter A, Zabelina T, Zander AR, Fehse B. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 2007 109 : 1316 1321.
7. Pardanani A, Lasho T, Smith G, Burns CJ, Fantino E, Tefferi A. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 2009 23 : 1441 1445.
8. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 2008 22 : 23 30.
9. Pardanani A, Hood J, Lasho T, et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 2007 21 : 1658 1668.
10. Lasho TL, Tefferi A, Hood JD, Verstovsek S, Gilliland DG, Pardanani A. TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients. Leukemia 2008 22 : 1790 1792.
11. Hussein K, Huang J, Lasho T, Pardanani A, Mesa RA, Williamson CM, Ketterling RP, Hanson CA, Van Dyke DL, Tefferi A. Karyotype complements the International Prognostic Scoring System for primary myelofibrosis. Eur J Haematol 2009 82 : 255 259.
12. Hussein K, Pardanani A, Van Dyke DL, Hanson CA, Tefferi A. International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. Blood 2009. In press.
13. Tefferi A, Mesa RA, Pardanani A, Hussein K, Schwager S, Hanson CA, Steensma DP. Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not. Am J Hematol 2009 84 : 265 267.
14. Thiele J, Vardiman JW, Pierre R, Brunning RD, Imbert M, Flandrin G. Chronic idiopathic myelofibrosis. In : Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumors: Tumours of the Haematopoietic and Lymphoid Tissues. Lyon, France : International Agency for Research on Cancer (IARC) Press 2001 : 35 8.
15. Cervantes F, Barosi G, Demory JL, Reilly J, Guarnone R, Dupriez B, Pereira A, Montserrat E. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol 1998 102 : 684 690.
16. Elliott MA, Verstovsek S, Dingli D, Schwager SM, Mesa RA, Li CY, Tefferi A. Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res 2007 31 : 1503 1509.
17. Dingli D, Schwager SM, Mesa RA, Li CY, Tefferi A. Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia. Cancer 2006 106 : 623 630.